The Medtronic Linq and Linq II implantable cardiac monitors (ICM) have become some of the most popular ICM devices on the market, partly because they are easy to insert.

In a recent interview with Cardiovascular Business, ACC President Edward T. A. Fry, MD, discussed some of the healthcare disparities that were highlighted during the COVID-19 pandemic. 

Randall Thompson, MD, immediate past president of the American Society of Nuclear Cardiology (ASNC), explains the current ASNC lobbying efforts.

Ty Gluckman, MD, explains the main points of the American College of Cardiology (ACC) expert consensus on the cardiovascular consequences stemming from a COVID-19 infection.

Leslee Shaw, PhD, director of the Blavatnik Family Women’s Health Research Institute at Mount Sinai Hospital in New York and former president of the Society of Cardiovascular Computed Tomography (SCCT) and the American Society of Nuclear Cardiology (ASNC), explains the role of cardiac computed tomography (CT) in the recent 2021 chest pain guidelines.

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.